PEG-MGF
PEG-MGF (PEGylated Mechano-Growth Factor) is a modified form of IGF-1 that stimulates myoblast proliferation and differentiation, with research applications in muscle repair, cardiac protection, bone healing, and neuroprotection.
PEGylated Mechano-Growth Factor (PEG-MGF) is a truncated and modified form of insulin-like growth factor 1 (IGF-1) conjugated with polyethylene glycol to extend its plasma half-life from minutes to several hours. Research shows that it stimulates myoblast proliferation and differentiation, with additional applications in cardiac protection, bone healing, cartilage repair, and neuroprotection.
Overview
MGF (Mechano-Growth Factor) is the product of alternative splicing of the IGF-1 gene, specifically the IGF-1Ec splice variant. It is naturally produced in response to mechanical stress on muscle tissue, such as exercise or injury. While MGF is potent, its extremely short half-life in plasma limits its systemic utility. PEGylation -- the attachment of polyethylene glycol -- solves this by reducing renal clearance and immune recognition, enabling systemic delivery via a single injection rather than requiring direct intramuscular administration into each target muscle.
Mechanism of Action
MGF stimulates the IGF-1 receptor with potency comparable to full-length IGF-1 at equimolar concentrations (Janssen et al., 2016). Downstream signaling promotes myoblast proliferation, satellite cell activation, and differentiation of precursor cells into mature muscle fibers. In injured tissue, MGF reduces inflammatory cytokine expression, attenuates oxidative stress, and recruits immune cells (macrophages and neutrophils) to the injury site. The peptide also modulates apoptotic pathways, reducing programmed cell death in hypoxic tissues. PEGylation preserves these biological activities while extending systemic bioavailability.
Reconstitution Calculator
PEG-MGF
PEGylated Mechano-Growth Factor (PEG-MGF) is a truncated and modified form of in
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Dental Applications
Research in human periodontal ligament cell cultures indicates that PEG-MGF improves osteogenic differentiation and boosts expression of MMP-1 and MMP-2 via the MEK/ERK1/2 pathway (Chen et al., 2019). These factors improve repair of the ligaments attaching teeth to bone, with potential applications in saving damaged or avulsed teeth after surgical re-implantation.
Skeletal Muscle
In a mouse model of muscle injury, MGF injected directly into muscle protects cells by decreasing expression of inflammatory hormones and reducing oxidative stress (Liu et al., 2019). Research by Sun et al. shows that MGF modulates muscle inflammation and improves recruitment of macrophages and neutrophils to injury sites (Sun et al., 2018). Both studies build on earlier findings that exercise-induced muscle damage stimulates release of IGF-1 splice variants closely related to MGF (Philippou et al., 2009).
Research in mice demonstrates a 25% increase in mean muscle fiber size when MGF is administered during exercise (Goldspink, 2005). In this study, MGF was injected directly into the muscle -- a limitation that PEG-MGF addresses by enabling systemic delivery through increased plasma half-life.
Heart Muscle Repair
Research from the University of Illinois Department of Bioengineering shows that MGF inhibits programmed cell death in cardiac muscle cells following hypoxia and recruits cardiac stem cells to the injury site. Rats administered MGF within eight hours of hypoxia showed less cell death and greater stem cell recruitment compared to controls (Doroudian et al., 2014).
Studies on localized delivery of MGF demonstrate improved cardiac function following heart attack by reducing pathologic hypertrophy. Rats treated with PEG-MGF showed better hemodynamics and less cardiac remodeling than untreated controls, with cardiomyocyte injury reduced by up to 35% (Pena et al., 2015).
Bone Repair and Growth
Research in rabbits indicates that PEG-MGF increases the rate of bone repair by boosting osteoblast proliferation. High-dose MGF treatment achieved at four weeks the same level of healing seen in controls at six weeks (Deng et al., 2011). This acceleration of bone healing has implications for reducing immobilization periods following fractures.
Cartilage Protection
MGF enhances the migration of chondrocytes from bone into cartilage through the RhoA/YAP pathway, improving cartilage health and repair (Jing et al., 2018). PEG-MGF is well suited for joint applications, as a single injection into a compromised joint space could maintain therapeutic levels for extended periods compared to the rapid degradation of unmodified MGF.
Neuroprotection
Studies reveal that elevated MGF levels in the brain reduce age-related neuron degeneration, with mice retaining cognitive functions and operating at peak cognitive performance longer into old age. The neuroprotective efficacy is age-dependent, with earlier MGF overexpression producing better initial and long-term outcomes (Walker, 2017).
MGF treatment has also been shown to improve muscle weakness and reduce motor neuron loss in mouse models of ALS. MGF is naturally expressed in the brain following hypoxic injury and is over-expressed in regions of greatest neuron regeneration, suggesting exogenous administration could reduce the impact of multiple neurological diseases (Dluzniewska et al., 2005).
Safety Profile
MGF is a naturally occurring splice variant of IGF-1, providing a basis for expected tolerability. In animal studies, both MGF and PEG-MGF have been administered without significant reported adverse effects at research doses. PEGylation itself is an established pharmaceutical technique with a well-characterized safety record, used in numerous approved therapeutics. As an IGF-1 pathway activator, theoretical concerns include potential effects on pre-existing malignancies, as IGF-1 signaling is implicated in cell proliferation and tumor biology. No formal human clinical trials have established a comprehensive safety profile for PEG-MGF. Potential interactions with insulin and growth hormone signaling pathways should be considered in research design.
Pharmacokinetic Profile
PEG-MGF — Pharmacokinetic Curve
Subcutaneous injection, Intramuscular injectionQuick Start
- Typical Dose
- 200-400mcg per injection
- Frequency
- 2-3x weekly, ideally post-workout
- Route
- Subcutaneous injection, Intramuscular injection
- Cycle Length
- 4-8 weeks
- Storage
- Refrigerate at 2-8°C; protect from light
Molecular Structure
- Formula
- C121H200N42O39 (base peptide)
- Length
- 24 amino acids
- CAS
- Not available
Research Indications
Muscle Repair
Primary mechanism activating dormant muscle satellite cells which fuse to damaged fibers.
Increases proliferative lifespan in younger muscle progenitor cells.
Increases activated satellite cell fusion capacity supporting repair and hypertrophy.
Tissue Regeneration
Animal studies suggest improved Achilles tendon injury outcomes.
Rabbit models demonstrated faster healing via osteoblast regulation.
Research indicates potential for articular cartilage injury models.
Recovery
Naturally upregulated after mechanical stress; supplementation may enhance processes.
Localized injection near injury sites supports targeted tissue repair.
Research Protocols
subcutaneous Injection
PEGylated mechano growth factor. Extended half-life enables systemic subcutaneous dosing.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Loading phase | 200 mcg | Once daily | Weeks 1-2 |
| Escalation 1 | 300 mcg | Once daily | Weeks 3-4 |
| Escalation 2 | 400 mcg | Once daily | Weeks 5-6 |
| Full dose | 500 mcg | Once daily | Weeks 7-8(Cycle 8 weeks, extendable to 16) |
Reconstitution Guide (2mg vial + 3mL BAC water)
- Wipe vial tops with alcohol swab
- Draw 3.0 mL bacteriostatic water into syringe
- Inject slowly down the inside wall of the peptide vial
- Gently swirl to dissolve — never shake
- Resulting concentration: 0.667 mg/mL
- For 200 mcg dose: draw 30 units (0.30 mL)
- For 300 mcg dose: draw 45 units (0.45 mL)
- For 500 mcg dose: draw 75 units (0.75 mL)
- Store reconstituted vial refrigerated at 2-8°C
Interactions
Peptide Interactions
Complementary mechanisms. BPC-157 promotes angiogenesis; PEG-MGF activates satellite cells. Popular recovery stack.
TB-500 reduces inflammation and promotes cell migration; PEG-MGF activates muscle stem cells.
Different regenerative pathways may enhance tissue repair through multiple mechanisms.
Both target IGF-1 pathways; combining risks receptor overstimulation. Reduce doses significantly if combined.
What to Expect
What to Expect
Reduced muscle soreness post-workout; subtle recovery improvements
Enhanced recovery between training; potential injury-related discomfort reduction
Optimal muscle repair effects; improved training capacity from better recovery
Benefits persist several weeks as tissue repair continues
Safety Profile
Common Side Effects
- Injection site soreness
- Mild fatigue
Contraindications
- Any history of cancer or neoplastic disease
- Pregnancy or breastfeeding
- Uncontrolled diabetes or severe hyperglycemia
Discontinue If
- Any unusual growths, lumps, or rapid tissue changes
- Severe injection site reactions beyond normal soreness
- Persistent headaches or vision changes
- Signs of hypoglycemia
- Unexpected swelling or edema
Quality Indicators
What to look for
- White or off-white fluffy cake appearance indicates proper freeze-drying
- Crystal clear solution after reconstitution with no particles
- Certificate of Analysis with HPLC purity testing (>98%)
Caution
- Minor clumping that dissolves with gentle swirling is normal
Red flags
- Collapsed or discolored powder suggests heat degradation
- Persistent cloudiness or visible particles indicate contamination
Frequently Asked Questions
References (17)
- [1]MGF-E Peptide Human Muscle Cell Study (2011)
- [2]MGF Inflammatory Response Study (2018)
- [3]Mechano-Growth Factor Minireview (2010)
- [13]Chen et al *Shanghai Kou Qiang Yi Xue* Shanghai Kou Qiang Yi Xue (2019)
- [15]
- [14]
- [16]Matheny et al — Mechano-growth factor E peptide: a tissue-specific modulator of IGF-1 signaling Growth Horm IGF Res (2022)
- [17]Philippou et al — The role of IGF-1 isoforms in muscle wasting conditions J Cachexia Sarcopenia Muscle (2023)
- [18]Wang et al — MGF E peptide protects against myocardial ischemia-reperfusion injury via PI3K/Akt pathway Cardiovasc Drugs Ther (2022)
- [4]Liu et al *Front Physiol* Front Physiol (2019)
- [6]Philippou et al *In Vivo* In Vivo (2009)
- [7]Janssen et al *PLoS ONE* PLoS ONE (2016)
- [8]Goldspink *Br J Sports Med* Br J Sports Med (2005)
- [9]
- [10]
- [11]
- [12]Jing et al *Exp Cell Res* Exp Cell Res (2018)
Pancreatic Polypeptide (PP)
Pancreatic polypeptide (PP) is a 36-amino acid peptide hormone released from PP cells of the pancreatic islets of Langerhans. A member of the NPY family alongside PYY and NPY, PP preferentially binds Y4 receptors and functions as an appetite suppressant, gastric motility modulator, and inhibitor of exocrine pancreatic secretion. PP is investigated as a satiety factor, metabolic regulator, and pancreatic tumor biomarker.
Pemvidutide
Pemvidutide (ALT-801) is a GLP-1/glucagon dual receptor agonist developed by Altimmune for obesity with muscle mass preservation and NAFLD/NASH. Phase 2 MOMENTUM trial demonstrated significant weight loss with favorable body composition changes.